Viagra (Sildenafil) vs Alprostadil (Caverject/MUSE): Head-to-Head Efficacy

Why No True Head-to-Head Trial Exists

Direct randomized comparisons between sildenafil and alprostadil are scarce because these drugs occupy different tiers in erectile dysfunction treatment algorithms. Sildenafil arrived in 1998 as a first-line oral option; alprostadil had already been established as a second-line injectable since 1995. The clinical pathway, rather than pharmaceutical rivalry, kept them in separate lanes.

The American Urological Association (AUA) guidelines position oral PDE5 inhibitors as initial pharmacotherapy, with intracavernosal injection reserved for PDE5 failures or contraindications. Most comparison data comes from cross-trial synthesis and small crossover studies. A 2003 Shabsigh crossover study (N=57 PDE5 non-responders) found that 85% of those men responded to intracavernosal alprostadil, but the design was not a true head-to-head because all participants had already failed sildenafil 1. The clinical reality is simpler than a direct efficacy race: sildenafil is tried first because it is an oral tablet, and alprostadil is the proven fallback.

Sildenafil: Key Efficacy Data

Sildenafil improves erectile function across a broad range of ED etiologies, with dose-dependent response rates between 56% and 82%. The drug works by inhibiting phosphodiesterase type 5, preserving cyclic GMP, and allowing nitric oxide-mediated smooth muscle relaxation in the corpus cavernosum.

The Goldstein 1998 NEJM trial enrolled 532 men with organic, psychogenic, or mixed ED in a dose-escalation design. At the 100 mg dose, 82% of attempts at intercourse were successful, compared with 24% in the placebo group [2]. The International Index of Erectile Function (IIEF) erectile function domain score improved from a baseline mean of approximately 12.2 to 25.1 in the sildenafil arm. A pooled analysis of 11 double-blind studies (N=2,883) confirmed that sildenafil 50-100 mg improved IIEF scores by a mean of 8-10 points versus 2-3 points for placebo, with a number needed to treat (NNT) of approximately 1.7 for "improved erections" on the Global Efficacy Question [3].

Subgroup performance matters. Diabetic men show lower response rates (approximately 56-63%), and post-radical-prostatectomy patients with bilateral nerve-sparing have reported rates around 43-60% 4. Sildenafil requires sexual arousal and intact nitric oxide signaling to work. When the neural pathway is severely damaged, the drug's ceiling drops, which is precisely where alprostadil's mechanism becomes relevant.

Alprostadil Injection (Caverject): Key Efficacy Data

Intracavernosal alprostadil bypasses the nitric oxide pathway entirely, acting directly on prostaglandin E1 receptors to relax corporal smooth muscle and increase penile blood flow. This mechanism makes it effective regardless of neural integrity.

The Linet 1996 NEJM trial randomized 296 men to alprostadil (dose-titrated from 2.5 to 20 mcg) or placebo. In the clinic, 87% of men had erections sufficient for intercourse at the optimal dose. During the six-month home-treatment phase, 70% of injections resulted in satisfactory intercourse [5]. Penile pain at the injection site occurred in 11% of injections but led to discontinuation in only 2% of patients.

A meta-analysis published in the Journal of Urology examining intracavernosal injection therapy found alprostadil monotherapy response rates of 70-94% across studies, with satisfaction rates of 87-93.5% among continued users [6]. The wide range reflects dose titration: men receiving individually optimized doses (up to 40 mcg) achieved the upper range. The European Association of Urology (EAU) notes that "intracavernosal injection of alprostadil is the most effective non-surgical treatment for erectile dysfunction," a characterization that remains current in their 2024 guidelines.

Dropout rates are the critical caveat. Between 40-68% of men prescribed intracavernosal injections discontinue within the first year, citing inconvenience, needle anxiety, and partner reluctance rather than poor efficacy 7.

MUSE (Intraurethral Alprostadil): A Third Route

MUSE delivers alprostadil as a 125-1,000 mcg pellet inserted into the urethra via a small applicator. It avoids needle injection but sacrifices some efficacy because drug absorption through the urethral mucosa is less efficient than direct intracavernosal delivery.

The Padma-Nathan 1997 NEJM study reported a 65.9% in-clinic response rate but only 43.2% home-use success for intercourse, compared with 9.4% for placebo [8]. This gap between clinic and home performance is characteristic of MUSE. Penile pain occurred in 10.8% of administrations, and hypotension (a systemic effect not seen with injection) affected 3.3% of users. MUSE may also be used in combination with a constriction band (ACTIS) to improve local drug retention, which raised home success rates to approximately 55% in a small follow-up study.

Dr. Culley Carson, a former chair of urology at the University of North Carolina, has described MUSE as "a useful option for men who want local therapy but refuse injection. Its response rate is lower than Caverject but substantially above placebo, placing it as a bridge between oral agents and ICI [intracavernosal injection]."

Mechanism Comparison: Why Etiology Matters

The fundamental pharmacologic difference between these drugs determines which patients benefit most. Sildenafil amplifies an existing nitric oxide signal. Alprostadil generates its own vasodilatory cascade.

For men with psychogenic ED, mild vasculogenic disease, or intact nerve pathways after nerve-sparing surgery, sildenafil's oral convenience and strong efficacy make it the obvious first step. The 2018 AUA/SMSNA guidelines on ED state that "PDE5 inhibitors should be offered as first-line therapy for ED" (conditional recommendation, Evidence Level B) [9]. For men with severe vascular disease, non-nerve-sparing prostatectomy, or diabetes-related neuropathy, the PDE5 pathway may be too compromised for sildenafil to deliver a response.

That is exactly where alprostadil shines. Because it acts through a receptor-mediated adenylate cyclase pathway (increasing cyclic AMP rather than cyclic GMP), it does not require endogenous nitric oxide. A study by Buvat 1998 showed that among diabetic men who failed sildenafil, 72% responded to intracavernosal alprostadil [10]. Post-prostatectomy patients without nerve sparing have shown alprostadil response rates of 60-67%, far exceeding the 15-20% sildenafil response rate in the same population.

Safety and Tolerability Profile

Sildenafil's systemic side effects include headache (16%), flushing (10%), dyspepsia (7%), nasal congestion (4%), and visual disturbance (3%), per the FDA prescribing information [11]. The drug is absolutely contraindicated with nitrate medications due to the risk of life-threatening hypotension. It requires caution with alpha-blockers and in patients with unstable cardiovascular disease.

Alprostadil's adverse effects are local. Penile pain with injection occurs in 11-44% of uses (depending on dose and study), corporal fibrosis in 5-7% with long-term use, and priapism (erection lasting more than 4 hours) in 1-3% of patients 12. MUSE adds urethral burning (8-12%) and occasional hypotension (1-3.3%). Alprostadil has no drug-drug interaction with nitrates, making it safe for men on nitroglycerin or isosorbide who cannot use any PDE5 inhibitor.

Dr. Arthur Burnett, professor of urology at Johns Hopkins, has noted that "the safety profile of intracavernosal alprostadil, when properly titrated, is well-established over three decades of use. The key risk, priapism, is dose-dependent and can be managed with patient education and conservative dosing protocols."

Switching from Sildenafil to Alprostadil

The clinical pathway for switching is well-defined. Men who fail adequate trials of at least two PDE5 inhibitors at maximum dose (sildenafil 100 mg taken on at least 6-8 separate occasions, at least 1 hour before intercourse, without heavy meals or excess alcohol) are candidates for alprostadil.

The switch requires an office visit. Dose titration of intracavernosal alprostadil begins at 2.5 mcg (1.25 mcg for neurogenic ED), increased in 2.5-5 mcg increments until erection sufficient for intercourse is achieved without exceeding 60 minutes duration 13. Patients are observed for at least 30 minutes after each in-office injection to monitor for prolonged erection. Home self-injection is only authorized after the patient demonstrates correct injection technique and understands the protocol for priapism (present to the emergency department if erection exceeds 4 hours).

For men intimidated by injection, MUSE represents an intermediate step. The titration typically starts at 250 mcg, increasing to 500 or 1,000 mcg. The patient should remain standing for 10 minutes after insertion to optimize absorption. Combining MUSE with a constriction band can improve results.

Some clinicians prescribe combination therapy: low-dose sildenafil (25-50 mg) plus MUSE or low-dose intracavernosal alprostadil. A small trial by Mydlo 2000 found that this combination rescued 31 of 40 (77.5%) men who had failed either agent alone [14].

Cost and Access Considerations

Generic sildenafil (20 mg tablets, available since 2017) costs $1-3 per dose in the United States. Brand Viagra at 100 mg ranges from $50-80 per tablet. Most insurance plans and GoodRx-style discount cards have made generic sildenafil affordable without prior authorization.

Caverject Impulse (20 mcg) lists at approximately $45-65 per injection. The generic alprostadil for injection is available at $25-40 per dose from compounding pharmacies. MUSE pellets (1,000 mcg) cost approximately $30-55 per dose. Insurance coverage for injectable or intraurethral alprostadil is inconsistent. Some plans require documentation of PDE5 inhibitor failure before authorizing coverage.

The per-use cost of alprostadil is significantly higher than generic sildenafil, which becomes relevant for men with active sexual frequency. A man using treatment 8 times per month would spend approximately $8-24 monthly on generic sildenafil versus $200-520 on brand Caverject.

Patient Selection: Which Drug for Which Man

Choosing between sildenafil and alprostadil is not about which drug is "better" in absolute terms. The decision follows etiology, comorbidities, and contraindications.

Sildenafil is preferred when: the man has mild-to-moderate vasculogenic or psychogenic ED, no nitrate use, no prior PDE5 failure, and values oral convenience. The 2018 AUA guideline reinforces this as a strong Grade B recommendation [9].

Alprostadil is preferred when: the man has failed PDE5 inhibitors at maximum dose after adequate trial, takes nitrate medications for coronary artery disease, has severe neurogenic ED (non-nerve-sparing prostatectomy, spinal cord injury), or has contraindications to PDE5 inhibitors including recent stroke or unstable angina. The EAU guidelines recommend intracavernosal alprostadil as second-line therapy with Level 1a evidence [15].

Patients with Peyronie's disease may prefer alprostadil injection because local prostaglandin E1 exposure could theoretically benefit plaque remodeling, though evidence for this is limited to small case series.

Efficacy in Special Populations

Diabetic men represent the largest subgroup with differential response. Sildenafil 100 mg yields success rates of 56-63% in type 2 diabetes [4], whereas intracavernosal alprostadil achieves 72-85% response rates in the same population [10]. The gap widens in type 1 diabetes with autonomic neuropathy, where PDE5 inhibitor response may drop below 40%.

After radical prostatectomy, bilateral nerve-sparing technique preserves some nitric oxide signaling, allowing sildenafil response rates of 43-60%. Without nerve sparing, sildenafil response drops to 15-20%, while alprostadil injection maintains 60-67% efficacy. Early penile rehabilitation protocols using nightly low-dose sildenafil (25 mg) or scheduled intracavernosal alprostadil (2-3 times weekly, starting 1 month post-surgery) are used at academic centers, though a 2015 Cochrane review found insufficient evidence to confirm that rehabilitation protocols improve long-term unassisted erectile function [16].

Men with spinal cord injury respond to both agents, but response rates favor alprostadil injection (88-95%) over sildenafil (approximately 75-83%), per a 2004 systematic review by Deforge [17].

The starting dose for intracavernosal alprostadil in neurogenic ED is 1.25 mcg, half the standard starting dose, because these patients are at higher risk for priapism due to intact local vascular responsiveness without descending inhibitory tone.